[Anaplastic thyroid carcinoma : new therapeutic approaches]

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Anaplastic thyroid cancer (ATC) is highly aggressive, with a median survival of 4 months and near 100% mortality.
• Current treatments like chemotherapy have limited efficacy in managing ATC.
• Urgent referral to specialized multidisciplinary centers is crucial upon diagnosis or suspicion of ATC.

Purpose of the Study:

• To highlight the critical role of molecular analyses in advancing ATC treatment.
• To emphasize the potential of novel targeted therapies and immunotherapies in improving patient outcomes.
• To underscore the specific indication of dabrafenib and trametinib for BRAF V600E-mutated ATC.

Main Methods:

• Review of current therapeutic strategies for anaplastic thyroid cancer.
• Analysis of the impact of molecular profiling on treatment selection.
• Evaluation of targeted therapy efficacy in BRAF V600E-mutated ATC.

Main Results:

• Molecular analyses are key to identifying actionable mutations in ATC.
• Targeted therapy, specifically dabrafenib and trametinib, shows promise for BRAF V600E-mutated ATC.
• Novel therapies offer improved outcomes compared to traditional chemotherapy.

Conclusions:

• Early diagnosis and multidisciplinary care are essential for ATC patients.
• BRAF V600E mutation status dictates the use of targeted therapies like dabrafenib and trametinib.
• Advancements in molecular diagnostics and targeted treatments are transforming ATC management.